.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
A recent ICMR study highlights the BPaL TB regimen India. This evaluation, published in the IJMR, shows that shorter treatment cycles for drug-resistant tuberculosis are cost-effective. Researchers at the NIRT compared six-month regimens against longer protocols. Their findings suggest these protocols enhance health outcomes and reduce costs.
The study focused on the BPaL regimen, including Bedaquiline, Pretomanid, and Linezolid. Additionally, it assessed the BPaLM regimen, which incorporates Moxifloxacin. The BPaL protocol is both effective and economical. The healthcare system saves Rs 379 per patient for every additional quality-adjusted life year gained. Consequently, this transition benefits both patients and providers.
Furthermore, the BPaLM regimen showed high cost-effectiveness. The analysis indicates an additional expenditure of just Rs 37 per patient per QALY. Both options offer a sustainable alternative to standard 9-to-11-month plans. Notably, these results underscore the importance of resource optimization.
Managing drug-resistant tuberculosis is traditionally very challenging. Long treatment durations often cause adverse effects and poor adherence. However, shorter all-oral regimens address these issues by simplifying the process. They reduce patient morbidity and enable a faster return to life. Moreover, these plans lower the overall burden on clinics. By aligning with national priorities, these regimens support TB elimination.
Q1: What is the primary advantage of the BPaL regimen?
The BPaL regimen reduces treatment duration from 18-20 months to just six months. Additionally, it is an all-oral treatment, which improves patient adherence.
Q2: How much does the health system save with the BPaL TB regimen India?
According to the ICMR study, the BPaL regimen saves Rs 379 per patient for each additional quality-adjusted life year gained.
Q3: Is the BPaLM regimen cost-effective?
Yes, the BPaLM regimen is highly cost-effective, costing only Rs 37 more per patient per additional QALY gained.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
ICMR study finds 6-month all-oral BPaL and BPaLM regimens for MDR-TB are highly cost-effective and improve patient outcomes compared to current long-term pl...
6 months ago
A clinical comparison of extravascular and subcutaneous implantable cardioverter-defibrillators, detailing patient selection, pacing capabilities, and implantation nuances.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
